1. ALLA AKTIER
  2. NYHETER
  3. BBS-BIOACTIVE BONE SUBSTITUTES

BBS-Bioactive Bone Substitutes

Nyheter BBS-Bioactive Bone Substitutes Nyheter alla bolag

BBS-Bioactive Bone Substitutes Plc: The Finnish Financial Supervisory Authority has imposed a penalty payment on a two current and one former member of Company’s Board of Directors

MARKN.

BBS-Bioactive Bone Substitutes Plc | Company Release | January 31, 2025 at 16:30:00 EET

BBS-Bioactive Bone Substitutes Plc: The Finnish Financial Supervisory Authority has imposed a penalty payment on a two current and one former member of Company’s Board of Directors

The Finnish Financial Supervisory Authority (the "FIN-FSA") has imposed a penalty payment of EUR 4,000 on Pekka Jalovaara and EUR 5,000 on Jarmo Halonen, current members of BBS-Bioactive Bone Substitute’s Board of Directors, and payment of EUR 9,000 on Ahti Paananen, a former member of BBS-Bioactive Bone Substitute’s Board of Directors, for discharging managerial responsibilities for the late notifications of transactions in BBS-Bioactive Bone Substitute’s shares made in their own account.

The decision of the FIN-FSA is not yet legally binding and can be appealed by the individuals.

For more information, please contact:
Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes Plc: The Finnish Financial Supervisory Authority has imposed a penalty payment on a two current and one former member of Company’s Board of Directors

Datum 2025-01-31, kl 15:30
Källa MFN
Bifogade filer
BBS-Bioactive Bone Substitutes Plc: The Finnish Financial Supervisory Authority has imposed a penalty payment on a two current and one former member of Company’s Board of Directors
Affiliate
200 kr till alla nya kunder! Just nu får alla nya kunder på Nordnet 200 kronor insatta i fonden Nordnet One Offensiv. Erbjudandet gäller mellan 1:e och 30:e september!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet